NovoCure Limited reported $699M of revenue over the trailing twelve months, +11% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $699M (to Q2 2026). Net income: −$149M, trailing twelve months to Q2 2026. Free cash flow: −$25M, trailing twelve months to Q2 2026. Operating margin: −22%, trailing twelve months to Q2 2026.

NVCRNovoCure Limited

Healthcare

$14.58+15% 1Y

$14.58

$10.0352 weeks$20.00

Latest close: back above its 200-day averageOct 9, 2026what changed →

NVCR as reported

NovoCure Limited reported $699M of revenue over the trailing twelve months, +11% on the year before. 10 reported series are charted on this page, each one as filed.

$699M

Revenue, trailing twelve months · to Q2 2026 · +11% against the twelve months before

Net income: −$149M
Net income · −13% year on year · trailing twelve months to Q2 2026
Free cash flow: −$25M
Free cash flow · −68% year on year · trailing twelve months to Q2 2026
Operating margin: −22%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NVCR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$699M	+11%	Q2 2026
Net income	−$149M	−13%	Q2 2026
EPS	−$1.30	−17%	Q2 2026
Gross margin	76%	n/a	Q2 2026
Operating margin	−22%	n/a	Q2 2026
Net margin	−21%	n/a	Q2 2026
ROE	−47%	n/a	Q2 2026
ROA	−18%	n/a	Q2 2026
ROIC	−26%	n/a	Q1 2024 · 9 quarters behind
Free cash flow	−$25M	−68%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.